Acknowledgments
Melanoma, P., rash, Cancer
MELANOMA, PATHOLOGY, CANCER
We thank all patients and their families for participation in the trial. The authors gratefully acknowledge the support of the study teams from the Netherlands Cancer Institute and Melanoma Institute Australia; we acknowledge the NKI-AVL Core Facility Molecular Pathology & Biobanking (CFMPB) and the Molecular Pathology department for supplying NKI-AVL Biobank material and lab support; Dr. E.H. Jaspars for review of the skin rash biopsies; S. Vanhoutvin for contractual management; and M. van Dijk, L.G. Grijpink-Ongering, Y. Wijnands, and M.J. Gregorio for administrative support and data management. The authors thank the intervention unit, animal laboratory, and flow cytometry facilities at the Netherlands Cancer Institute for help with animal experiments. In addition, we would like to thank Johanna A. Stunnenberg, Esmée P. Hoefsmit, and Paula T. van Royen for technical help with mice tissue processing for flow cytometry analysis.Financial support for the trial was provided by 4SC AG, Planegg-Martinsried, Germany. G.V. Long, R.A. Scolyer, and A.M. Menzies are supported by National Health and Medical Research Council (NHMRC) investigator grants. G.V. Long is supported by an NHMRC investigator grant (2021/GNT2007839). G.V. Long is also supported by the University of Sydney Medical Foundation. R.A. Scolyer is supported by an NHMRC Practitioner Fellowship (APP1141295). Open Access funding provided by the Netherlands Cancer Institute.Author contributions: Preclinical mice experiments: D. Rao and C.U. Blank designed the preclinical experiments. D. Rao conducted the experiments together with the help of intervention unit at Netherlands Cancer Institute, and data were analyzed by D. Rao. Quality control and analysis of RNA sequencing data was by P. Dimitriadis. D. Rao was supervised by C.U. Blank and D.S. Peeper. DONIMI trial: C.U. Blank and I.L.M. Reijers designed the trial and wrote the trial protocol. G.V. Long gave input on the trial design and reviewed the protocol. J.M. Versluis, A.C.J. van Akkooi, and B.A. van de Wiel reviewed the protocol. I.L.M. Reijers, J.M. Versluis, A.M. Menzies, A.J. Spillane, M.W. Wouters, W.M.C. Klop, W.J. van Houdt, A.C.J. van Akkooi, G.V. Long, and C.U. Blank recruited and treated patients and collected data. C.U. Blank, P. Dimitriadis, I.L.M. Reijers, L.J.W. Bosch, A. Broeks, S. Cornelissen, J. Bouwman, and other colleagues from the CFMPB and Molecular Pathology department worked on the development of the IFN-γ signature pipeline and/or the signature assessment during the trail. R.V. Rawson, R.A. Scolyer, and B.A. van de Wiel reviewed and scored the pathology of all cases. The CFMPB performed the PD-L1 staining, and J. Sanders determined the PD-L1 TPS scores. M. Lopez-Yurda and I.L.M. Reijers performed statistical analysis of the clinical data. P. Dimitriadis performed NanoString translational analyses. Y. Wijnands and L.G. Grijpink-Ongering contributed to central and local data management. Marloes van Dijk and Mary Jane Gregorio were clinical project managers of the trial. Manuscript: I.L.M. Reijers, D. Rao, and C.U. Blank wrote the first draft of the manuscript. All authors interpreted the data, reviewed the manuscript, and approved the final version.